支链氨基酸转氨酶1在上皮性卵巢癌中的表达及临床意义
| 作者: |
1李丹,
1吴文
1 华中科技大学同济医学院附属协和医院西院妇产科，武汉 430022 |
| 通讯: |
吴文
Email: wuwen783@sohu.com |
| DOI: | 10.3978/j.issn.2095-6959.2020.07.008 |
摘要
目的：探讨上皮性卵巢癌(epithelial ovarian cancer，EOC)患者癌组织中支链氨基酸转氨酶1(branched-chain amino-acid transaminase 1，BCAT1)的表达及临床意义。方法：采用免疫组织化学法检测133例EOC癌组织中BCAT1表达情况，根据免疫组织化学评分分为BCAT1高表达组(n=41)及低表达组(n=92)，卡方检验分析BCAT1的表达与临床病理因素间的关系，Kaplan-Meier生存曲线和对数秩检验比较BCAT1高、低表达组患者无瘤生存率及总生存率的差异，Cox比例风险模型分析影响EOC患者预后的因素。结果：BCAT1表达与宫颈癌国际妇产科联盟(Federation International of Gynecology and Obstetrics，FIGO)分期(P=0.004)、淋巴结转移(P=0.001)显著相关，与糖类抗原125(CA125)水平(P=0.538)、组织学类型(P=0.306)、年龄(P=0.524)、肿瘤大小(P=0.632)、腹水(P=0.178)无显著相关性(P>0.05)。BCAT1高表达组患者1年、3年无瘤生存率及总生存率显著低于BCAT1低表达组(P<0.001)。单因素分析示CA125(P<0.001)、肿瘤大小(P=0.003)、组织学类型(P=0.004)、淋巴结转移(P<0.001)、FIGO分期(P<0.001)和BCAT1表达(P<0.001)是影响EOC患者无瘤生存率的危险因素。多因素分析示FIGO分期(P<0.001)和BCAT1表达(P=0.013)是影响EOC患者无瘤生存率的独立危险因素。单因素分析示FIGO分期(P=0.022)、BCAT1表达(P=0.004)及淋巴结转移(P=0.046)是影响EOC患者总生存率的危险因素；多因素分析示FIGO分期(P<0.001)和BCAT1表达(P=0.025)是影响EOC患者总生存率的独立危险因素。结论：EOC癌组织中BACT1高表达，且与FIGO分期、淋巴结转移和预后显著相关，是影响EOC患者预后的分子标志物。
关键词：
上皮性卵巢癌；支链氨基酸转氨酶1；临床意义
Expression of branched-chain amino-acid transaminase 1 in epithelial ovarian cancer and its clinical significance
CorrespondingAuthor: WU Wen Email: wuwen783@sohu.com
DOI: 10.3978/j.issn.2095-6959.2020.07.008
Abstract
Objective: To investigate the expression of branched-chain amino-acid transaminase 1 (BCAT1) in cancer tissues of patients with epithelial ovarian cancer and its clinical significance. Methods: Immunohistochemical method was used to detect the expression of BCAT1 in 133 cases of epithelial ovarian cancer. The epithelial ovarian cancer was divided into 2 groups according to the immunohistochemical score (high expression of BCAT1: n=41; low expression of BCAT1: n=92). Chi-square test was used to analyze the relationship between BCAT1 expression and clinicopathological factors. Kaplan-Meier survival curve and logarithmic rank test were used to compare the difference of disease-free survival rate and overall survival rate between high and low BCAT1 expression groups. Cox proportional hazard model was used to analyze the prognostic factors of EOC patients. Results: BCAT1 expression was significantly correlated with FIGO stage (P=0.004), lymph node metastasis (P=0.001), but not with CA125 level (P=0.538), histological type (P=0.306), age (P=0.524), tumor size (P=0.632), and ascites (P=0.178). The 1-year and 3-year disease-free survival rate and overall survival rate of BCAT1 high expression group were significantly lower than those of BCAT1 low expression group (P<0.001). Univariate analysis showed that CA125 (P<0.001), tumor size (P=0.003), histological type (P=0.004), lymph node metastasis (P<0.001), FIGO staging (P<0.001) and BCAT1 expression (P<0.001) were risk factors for the survival rate of EOC patients. Multivariate analysis showed that FIGO staging (P<0.001) and BCAT1 expression (P=0.013) were independent risk factors for EOC patients’ disease-free survival. Univariate analysis showed that FIGO staging (P=0.022), BCAT1 expression (P=0.004) and lymph node metastasis (P=0.046) were risk factors affecting the overall survival rate of EOC patients. Multivariate analysis showed that FIGO staging (P<0.001) and BCAT1 expression (P=0.025) were independent risk factors for the overall survival rate of EOC patients. Conclusion: BACT1 is highly expressed in EOC cancer tissues, which is significantly correlated with FIGO staging, lymph node metastasis and prognosis. BACT1 is a molecular marker affecting the prognosis of EOC patients.
Keywords：
epithelial ovarian cancer; branched-chain amino-acid transaminase 1; clinical significance